{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:20:21Z","timestamp":1792797621668,"version":"4.5.0"},"reference-count":54,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Older adults with multiple myeloma (MM) are a growing population, and personalizing treatment based on disease and health status is imperative. Similar to MM staging systems that provide disease-related prognostic information, myeloma-specific frailty tools can better identify subgroups at greatest risk for treatment-related toxicity and early treatment discontinuation, as well as predict overall survival. Several myeloma-specific validated tools are well studied. Although these fitness\/frailty scores have shaped our understanding of the heterogeneity among older adults with myeloma, the application of such scores in treatment decision making (ie, transplant considerations, relapse) is an unmet need. Here we outline how to incorporate frailty assessments in the evaluation of older adults with MM in the clinical setting with consideration of other factors such as patient preferences, treatment risks\/benefits, life expectancy, and disease biology.<\/jats:p>","DOI":"10.1182\/hematology.2021000231","type":"journal-article","created":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T12:15:43Z","timestamp":1639138543000},"page":"46-54","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":16,"title":["Treatment of older adult or frail patients with multiple myeloma"],"prefix":"10.1182","volume":"2021","author":[{"given":"Shakira J.","family":"Grant","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Hematology, The University of North Carolina at Chapel Hill, Chapel Hill, NC; Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciara L.","family":"Freeman","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley E.","family":"Rosko","sequence":"additional","affiliation":[{"name":"Division of Hematology, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,12,10]]},"reference":[{"issue":"5","key":"2021121012075943600_hem2021000231C1","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/jgs.15715","article-title":"Geriatric assessment in older adults with multiple myeloma","volume":"67","author":"Wildes","year":"2019","journal-title":"J Am Geriatr Soc"},{"issue":"12","key":"2021121012075943600_hem2021000231C2","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1001\/jamaoncol.2018.4654","article-title":"Cognitive impairment among older patients with hematologic cancers\u2014reply","volume":"4","author":"Hshieh","year":"2018","journal-title":"JAMA Oncol"},{"issue":"3","key":"2021121012075943600_hem2021000231C3","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.leukres.2013.12.018","article-title":"The relevance of a geriatric assessment for elderly patients with a haematological malignancy\u2014a systematic review","volume":"38","author":"Hamaker","year":"2014","journal-title":"Leuk Res"},{"issue":"4","key":"2021121012075943600_hem2021000231C4","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s12185-014-1539-5","article-title":"Limited value of the international staging system for predicting long-term outcome of transplant-ineligible, newly diagnosed, symptomatic multiple myeloma in the era of novel agents","volume":"99","author":"Kuroda","year":"2014","journal-title":"Int J Hematol"},{"issue":"2","key":"2021121012075943600_hem2021000231C5","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/s41375-019-0595-5","article-title":"The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial","volume":"34","author":"Pawlyn","year":"2020","journal-title":"Leukemia"},{"key":"2021121012075943600_hem2021000231C6","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"issue":"5","key":"2021121012075943600_hem2021000231C7","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3324\/haematol.2016.162693","article-title":"A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients","volume":"102","author":"Engelhardt","year":"2017","journal-title":"Haematologica"},{"issue":"1","key":"2021121012075943600_hem2021000231C8","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41375-019-0539-0","article-title":"A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial","volume":"34","author":"Facon","year":"2020","journal-title":"Leukemia"},{"issue":"6","key":"2021121012075943600_hem2021000231C9","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"issue":"3","key":"2021121012075943600_hem2021000231C10","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1016\/S2352-3026(18)30220-5","article-title":"A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK myeloma research alliance risk profile): a development and validation study","volume":"6","author":"Cook","year":"2019","journal-title":"Lancet Haematol"},{"issue":"11","key":"2021121012075943600_hem2021000231C11","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/ajh.24532","article-title":"N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma","volume":"91","author":"Milani","year":"2016","journal-title":"Am J Hematol"},{"issue":"6","key":"2021121012075943600_hem2021000231C12","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.clml.2012.06.008","article-title":"Assessment of vulnerability measures and their effect on survival in a real-life population of multiple myeloma patients registered at Marche Region Multiple Myeloma Registry","volume":"12","author":"Offidani","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"2021121012075943600_hem2021000231C13","doi-asserted-by":"crossref","first-page":"M146","DOI":"10.1093\/gerona\/56.3.M146","article-title":"Frailty in older adults: evidence for a phenotype","volume":"56","author":"Fried","year":"2001","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"10","key":"2021121012075943600_hem2021000231C14","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"2021121012075943600_hem2021000231C15","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2017-07-795047","article-title":"Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma","volume":"131","author":"Facon","year":"2018","journal-title":"Blood"},{"issue":"7","key":"2021121012075943600_hem2021000231C16","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1038\/s41375-020-0713-4","article-title":"Validation of the FIRST simplified frailty scale using the ECOG performance status instead of patient-reported activities","volume":"34","author":"Stege","year":"2020","journal-title":"Leukemia"},{"issue":"5","key":"2021121012075943600_hem2021000231C17","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.3324\/haematol.2019.242958","article-title":"Structured assessment of frailty in multiple myeloma as a paradigm of individualized treatment algorithms in cancer patients at advanced age","volume":"105","author":"Engelhardt","year":"2020","journal-title":"Haematologica"},{"issue":"8","key":"2021121012075943600_hem2021000231C18","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/s41375-018-0142-9","article-title":"Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)","volume":"32","author":"Larocca","year":"2018","journal-title":"Leukemia"},{"issue":"4","key":"2021121012075943600_hem2021000231C19","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jgo.2020.12.001","article-title":"Transplant-ineligible newly diagnosed multiple myeloma: current and future approaches to clinical care: a Young International Society of Geriatric Oncology review paper","volume":"12","author":"Grant","year":"2021","journal-title":"J Geriatr Oncol"},{"issue":"2","key":"2021121012075943600_hem2021000231C20","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/bjh.15261","article-title":"A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma","volume":"182","author":"O'Donnell","year":"2018","journal-title":"Br J Haematol"},{"issue":"22","key":"2021121012075943600_hem2021000231C21","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"key":"2021121012075943600_hem2021000231C22","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1182\/blood-2020-134847","article-title":"Updated analysis of daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM): the phase 3 MAIA study","volume":"136","author":"Kumar","year":"2020","journal-title":"Blood"},{"key":"2021121012075943600_hem2021000231C23","first-page":"1","article-title":"Newly diagnosed myeloma in 2020","volume":"40","author":"Moreau","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"7","key":"2021121012075943600_hem2021000231C24","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1007\/s12325-021-01824-5","article-title":"Initial therapeutic approaches to patients with multiple myeloma","volume":"38","author":"Berbari","year":"2021","journal-title":"Adv Ther"},{"issue":"7","key":"2021121012075943600_hem2021000231C25","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41408-021-00524-1","article-title":"Treatment patterns and outcomes in elderly patients with newly diagnosed multiple myeloma: results from the Connect\u00ae MM Registry","volume":"11","author":"Lee","year":"2021","journal-title":"Blood Cancer J"},{"issue":"suppl 1","key":"2021121012075943600_hem2021000231C26","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1182\/blood-2019-126207","article-title":"Frailty-adjusted therapy in transplant non-eligible patients with newly diagnosed multiple myeloma (FiTNEss): a UK myeloma research alliance study, myeloma XIV","volume":"134","author":"Cairns","year":"2019","journal-title":"Blood"},{"key":"2021121012075943600_hem2021000231C27","unstructured":"PETHEMA Foundation. Treatment for elderly fit newly diagnosed multiple myeloma patients aged between 65 and 80 years. Accessed 1Apr2021. https:\/\/ClinicalTrials.gov\/show\/NCT03742297"},{"key":"2021121012075943600_hem2021000231C28","unstructured":"Onlus FEI. Study to determine the efficacy and safety of standard schedule versus a new algorithm of dose reductions in elderly and unfit newly diagnosed multiple myeloma patients receiving lenalidomide plus steroids. Accessed 1Apr2021. https:\/\/ClinicalTrials.gov\/show\/NCT02215980"},{"key":"2021121012075943600_hem2021000231C29","unstructured":"Leeds Uo, UK CR, Takeda, et al. Myeloma XIV: frailty-adjusted therapy in transplant non-eligible patients with newly diagnosed multiple myeloma. Accessed 1Apr2021. https:\/\/ClinicalTrials.gov\/show\/NCT03720041"},{"issue":"suppl 1","key":"2021121012075943600_hem2021000231C30","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1182\/blood-2019-121694","article-title":"Efficacy and tolerability of ixazomib, daratumumab and low dose dexamethasone (Ixa Dara dex) in unfit and frail newly diagnosed multiple myeloma (NDMM) patients; results of the interim efficacy analysis of the phase II HOVON 143 study","volume":"134","author":"Stege","year":"2019","journal-title":"Blood"},{"issue":"4","key":"2021121012075943600_hem2021000231C31","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41408-019-0205-9","article-title":"Current status of autologous stem cell transplantation for multiple myeloma","volume":"9","author":"Al Hamed","year":"2019","journal-title":"Blood Cancer J"},{"issue":"39","key":"2021121012075943600_hem2021000231C32","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1200\/EDBK_239067","article-title":"Approach to the older adult with multiple myeloma","volume":"93","author":"Mina","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"3","key":"2021121012075943600_hem2021000231C33","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"issue":"23","key":"2021121012075943600_hem2021000231C34","doi-asserted-by":"crossref","first-page":"5077","DOI":"10.1002\/cncr.33171","article-title":"Age no bar: a CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma","volume":"126","author":"Munshi","year":"2020","journal-title":"Cancer"},{"issue":"1","key":"2021121012075943600_hem2021000231C35","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jgo.2019.05.014","article-title":"Autologous stem cell transplant in older patients (age \u2265 65) with newly diagnosed multiple myeloma: a systematic review and meta-analysis","volume":"11","author":"Mian","year":"2020","journal-title":"J Geriatr Oncol"},{"key":"2021121012075943600_hem2021000231C36","article-title":"Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trial [published online 3 December 2020]","author":"Pawlyn","journal-title":"Haematologica"},{"issue":"2","key":"2021121012075943600_hem2021000231C37","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41408-021-00432-4","article-title":"Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life","volume":"11","author":"Terpos","year":"2021","journal-title":"Blood Cancer J"},{"key":"2021121012075943600_hem2021000231C38","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.2147\/PPA.S259612","article-title":"Myeloma patient value mapping: a discrete choice experiment on myeloma treatment preferences in the UK","volume":"14","author":"Fifer","year":"2020","journal-title":"Patient Prefer Adherence"},{"issue":"3","key":"2021121012075943600_hem2021000231C39","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.bbmt.2013.12.557","article-title":"Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma","volume":"20","author":"Saad","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2021121012075943600_hem2021000231C40","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.bbmt.2015.03.002","article-title":"Hematopoietic stem cell transplantation for multiple myeloma: guidelines from the American Society for Blood and Marrow Transplantation","volume":"21","author":"Shah","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021121012075943600_hem2021000231C41","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1200\/EDBK_175171","article-title":"Myeloma in elderly patients: when less is more and more is more","volume":"37","author":"Rosko","year":"2017","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"10","key":"2021121012075943600_hem2021000231C42","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1038\/s41375-019-0561-2","article-title":"Relapsed refractory multiple myeloma: a comprehensive overview","volume":"33","author":"Bazarbachi","year":"2019","journal-title":"Leukemia"},{"key":"2021121012075943600_hem2021000231C43","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1200\/EDBK_320129","article-title":"When and how to treat relapsed multiple myeloma","volume":"41","author":"Nathwani","year":"2021","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"3, suppl","key":"2021121012075943600_hem2021000231C44","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1188\/08.CJON.S1.53-62","article-title":"Steroid-associated side effects in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board","volume":"12","author":"Faiman","year":"2008","journal-title":"Clin J Oncol Nurs"},{"issue":"1","key":"2021121012075943600_hem2021000231C45","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"issue":"22","key":"2021121012075943600_hem2021000231C46","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1182\/blood.2020009507","article-title":"Dose\/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma","volume":"137","author":"Larocca","year":"2021","journal-title":"Blood"},{"issue":"10214","key":"2021121012075943600_hem2021000231C47","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"2021121012075943600_hem2021000231C48","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1182\/asheducation-2018.1.88","article-title":"Approach to the treatment of the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a US hematologist and a geriatric hematologist","volume":"2018","author":"Wildes","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"21","key":"2021121012075943600_hem2021000231C49","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1182\/bloodadvances.2020001965","article-title":"Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and\/or refractory multiple myeloma","volume":"4","author":"Facon","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"2021121012075943600_hem2021000231C50","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/bjh.14549","article-title":"Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study","volume":"177","author":"Dimopoulos","year":"2017","journal-title":"Br J Haematol"},{"issue":"10","key":"2021121012075943600_hem2021000231C51","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","article-title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol"},{"issue":"7","key":"2021121012075943600_hem2021000231C52","first-page":"953","article-title":"Once-weekly vs twice-weekly carfilzomib (K) dosing plus dexamethasone (d) in patients with relapsed and refractory multiple myeloma (RRMM): results of the randomized phase 3 study ARROW","volume":"19","author":"Mateos","year":"2018","journal-title":"J Clin Oncol"},{"issue":"9","key":"2021121012075943600_hem2021000231C53","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1002\/cam4.2945","article-title":"Once-weekly (70\u200amg\/m2) vs twice-weekly (56\u200amg\/m2) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: a post hoc analysis of the ENDEAVOR, ARROW, and CHAMPION-1 trials","volume":"9","author":"Moreau","year":"2020","journal-title":"Cancer Med"},{"issue":"22","key":"2021121012075943600_hem2021000231C54","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1200\/JCO.19.00231","article-title":"Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma","volume":"37","author":"Cornell","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2021\/1\/46\/1852113\/46grant.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2021\/1\/46\/1852113\/46grant.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T12:16:30Z","timestamp":1639138590000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2021\/1\/46\/482971\/Treatment-of-older-adult-or-frail-patients-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,10]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12,10]]},"published-print":{"date-parts":[[2021,12,10]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2021000231","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,10]]},"published":{"date-parts":[[2021,12,10]]}}}